Search

Displaying results 1311 - 1320 of 4262 in total
  1. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

  2. Drug

    Iopamidol

    go.drugbank.com/drugs/DB08947
    ApprovedInvestigational

    Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

  3. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. … By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation.

  4. Drug

    Gefitinib

    go.drugbank.com/drugs/DB00317
    ApprovedInvestigational

    It is marketed by AstraZeneca under the trade name Iressa.

  5. Drug

    Sucralfate

    go.drugbank.com/drugs/DB00364
    ApprovedInvestigational

    It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. … It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among

  6. Drug

    Lactitol

    go.drugbank.com/drugs/DB12942
    Approved

    [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803]

  7. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940] By preventing this aberrant signaling, it reduces the formation of new abnormal bone.[L63940] It is administered by intravenous infusion every four weeks. … [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.

  8. Drug

    Chlorquinaldol

    go.drugbank.com/drugs/DB13306
    Approved

    Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]

  9. Drug

    Enfuvirtide

    go.drugbank.com/drugs/DB00109
    ApprovedInvestigational

    The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.

  10. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    Romosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921]. Romosozumab was granted FDA approval on April 9,2019[L5921]. … In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months